# EDGAR Filing Document

**Accession Number:** 0001960682
**File Stem:** 0000000000-23-001569
**Filing Date:** 2023-2
**Character Count:** 4315
**Document Hash:** ea0c7ed587ad20f2beb6efbfb095c8f7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-001569.hdr.sgml**: 20231010

**ACCESSION NUMBER**: 0000000000-23-001569

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230215

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Starpax Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001960682
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 6615 ABRAMS STREET
- **CITY:** MONTREAL
- **STATE:** A8
- **ZIP:** H4S1V9
- **BUSINESS PHONE:** 514-427-3004

**MAIL ADDRESS:**
- **STREET 1:** 6615 ABRAMS STREET
- **CITY:** MONTREAL
- **STATE:** A8
- **ZIP:** H4S1V9
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001960682-23-000001

## Text-Extract

```

United States securities and exchange commission logo

                             February 15, 2023

       Jean-Fran  ois Pruneau
       Chief Operating Officer
       Starpax Biopharma Inc.
       2500-1000 boul. Rene-Levesque West
       Montreal, Quebec. Canada H3B 5C9

                                                        Re: Starpax Biopharma
Inc.
                                                            Offering Statement
on Form 1-A
                                                            Filed February 9,
2023
                                                            File No. 024-12149

       Dear Jean-Fran  ois Pruneau:

                                                        This is to advise you
that we do not intend to review your offering statement.

               We will consider qualifying your offering statement at your
request. If a participant in
       your offering is required to clear its compensation arrangements with
FINRA, please have
       FINRA advise us that it has no objections to the compensation
arrangements prior to
       qualification.

               We remind you that the company and its management are
responsible for the accuracy
       and adequacy of their disclosures, notwithstanding any review, comments,
action or absence of
       action by the staff. We also remind you that, following qualification of
your Form 1-A, Rule 257
       of Regulation A requires you to file periodic and current reports,
including a Form 1-K which
       will be due within 120 calendar days after the end of the fiscal year
covered by the report.

                                                        Please contact Jimmy
McNamara at 202-551-7349 with any questions.

                             Sincerely,

                             Division of Corporation Finance

                             Office of Life Sciences
       cc:                                              Nick Antaki

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

February 15, 2023

Jean-François Pruneau
Chief Operating Officer
Starpax Biopharma Inc.
2500-1000 boul. Rene-Levesque West
Montreal, Quebec. Canada H3B 5C9

**Re: Starpax Biopharma Inc.**
**Offering Statement on Form 1-A**
**Filed February 9, 2023**
**File No. 024-12149**

Dear Jean-François Pruneau:

This is to advise you that we do not intend to review your offering statement.

We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257 of Regulation A requires you to file periodic and current reports, including a Form 1-K which will be due within 120 calendar days after the end of the fiscal year covered by the report.

Please contact Jimmy McNamara at 202-551-7349 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Nick Antaki